{"title":"Frequencies of HLA Alleles in Patients with Acute Lymphoblastic and Myeloid Leukemia","authors":"Rasime Derya Güleç, F. Arslan","doi":"10.36472/msd.v10i8.994","DOIUrl":null,"url":null,"abstract":"Objective: Our objective was to investigate the potential correlation between human leukocyte antigens (HLA) - specifically, HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes - and patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).\nMaterial and Methods: We conducted an analysis of HLA allele frequencies among 393 patients with ALL, 431 patients with AML, and a control group comprising 564 healthy donors. Additionally, we explored the variation in HLA allele distribution between pediatric and adult patients diagnosed with ALL.\nResults: In comparison to the donor group, a heightened frequency of HLA-A*32 antigen was observed in AML patients (p=0.015, OR: 1.682). Conversely, the frequencies of HLA-B*55 (p=0.027, OR: 0.545) in ALL patients, HLA-B*14 (p=0.023, OR: 0.397), and HLA-B*55 (p=0.04, OR: 0.604) in AML patients were notably diminished. Notably, there were no discernible differences in HLA Class II allele frequency and analysis between the patient and control groups. Moreover, a significant distinction in the frequencies of HLA-A*25 (p=0.019, OR: 8.426) and DRB1*04 (p=0.049, OR: 1.491) was identified between pediatric patients (n=165) and adult patients (n=228) with ALL.\nConclusion: The findings indicate that HLA-A*32 might serve as a genetic predisposing factor for AML, and HLA-A*25 and DRB1*04 could be potential genetic risk factors for pediatric ALL patients. Conversely, HLA-B*55 appears to be a potential protective factor against both forms of acute leukemia.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Science and Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36472/msd.v10i8.994","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Our objective was to investigate the potential correlation between human leukocyte antigens (HLA) - specifically, HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes - and patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Material and Methods: We conducted an analysis of HLA allele frequencies among 393 patients with ALL, 431 patients with AML, and a control group comprising 564 healthy donors. Additionally, we explored the variation in HLA allele distribution between pediatric and adult patients diagnosed with ALL.
Results: In comparison to the donor group, a heightened frequency of HLA-A*32 antigen was observed in AML patients (p=0.015, OR: 1.682). Conversely, the frequencies of HLA-B*55 (p=0.027, OR: 0.545) in ALL patients, HLA-B*14 (p=0.023, OR: 0.397), and HLA-B*55 (p=0.04, OR: 0.604) in AML patients were notably diminished. Notably, there were no discernible differences in HLA Class II allele frequency and analysis between the patient and control groups. Moreover, a significant distinction in the frequencies of HLA-A*25 (p=0.019, OR: 8.426) and DRB1*04 (p=0.049, OR: 1.491) was identified between pediatric patients (n=165) and adult patients (n=228) with ALL.
Conclusion: The findings indicate that HLA-A*32 might serve as a genetic predisposing factor for AML, and HLA-A*25 and DRB1*04 could be potential genetic risk factors for pediatric ALL patients. Conversely, HLA-B*55 appears to be a potential protective factor against both forms of acute leukemia.